Previous Close | 13.00 |
Open | 13.00 |
Bid | 12.53 x 100 |
Ask | 13.10 x 100 |
Day's Range | 12.52 - 13.01 |
52 Week Range | 1.44 - 19.41 |
Volume | |
Avg. Volume | 45,095 |
Market Cap | 362.853M |
Beta (5Y Monthly) | 1.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.37 |
Earnings Date | May 12, 2024 - May 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.50 |
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington. Details of the presentations are as follow
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences: Conference
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq"). The Company's common sto